Raymond James & Associates’s Labcorp LH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | $27.8M | Buy |
124,336
+5,786
| +5% | +$1.27M | 0.02% | 656 |
|
|
2024
Q2 | $24.1M | Sell |
118,550
-759
| -0.6% | -$154K | 0.02% | 678 |
|
|
2024
Q1 | $26.1M | Buy |
119,309
+1,066
| +0.9% | +$235K | 0.02% | 659 |
|
|
2023
Q4 | $26.9M | Sell |
118,243
-18,237
| -13% | -$3.83M | 0.02% | 621 |
|
|
2023
Q3 | $27.4M | Buy |
136,480
+5,831
| +4% | +$1.23M | 0.02% | 557 |
|
|
2023
Q2 | $27.1M | Buy |
130,649
+22,817
| +21% | +$4.43M | 0.02% | 569 |
|
|
2023
Q1 | $21.3M | Buy |
107,832
+1,729
| +2% | +$356K | 0.02% | 654 |
|
|
2022
Q4 | $21.5M | Sell |
106,103
-221
| -0.2% | -$43.2K | 0.02% | 633 |
|
|
2022
Q3 | $18.7M | Buy |
106,324
+14,879
| +16% | +$3.05M | 0.02% | 635 |
|
|
2022
Q2 | $18.4M | Sell |
91,445
-4,914
| -5% | -$1.05M | 0.02% | 657 |
|
|
2022
Q1 | $21.8M | Buy |
96,359
+16,459
| +21% | +$3.87M | 0.02% | 654 |
|
|
2021
Q4 | $21.6M | Buy |
79,900
+2,351
| +3% | +$582K | 0.02% | 703 |
|
|
2021
Q3 | $18.8M | Buy |
77,549
+10,002
| +15% | +$2.52M | 0.02% | 745 |
|
|
2021
Q2 | $16M | Buy |
67,547
+2,176
| +3% | +$496K | 0.01% | 821 |
|
|
2021
Q1 | $14.3M | Buy |
65,371
+4,454
| +7% | +$894K | 0.01% | 834 |
|
|
2020
Q4 | $10.7M | Sell |
60,917
-21,415
| -26% | -$3.7M | 0.01% | 914 |
|
|
2020
Q3 | $13.3M | Sell |
82,332
-36,481
| -31% | -$5.78M | 0.02% | 718 |
|
|
2020
Q2 | $17M | Sell |
118,813
-4,017
| -3% | -$556K | 0.02% | 588 |
|
|
2020
Q1 | $13.3M | Sell |
122,830
-7,737
| -6% | -$1.11M | 0.02% | 621 |
|
|
2019
Q4 | $19M | Sell |
130,567
-2,456
| -2% | -$355K | 0.02% | 600 |
|
|
2019
Q3 | $19.2M | Buy |
133,023
+2,202
| +2% | +$321K | 0.03% | 561 |
|
|
2019
Q2 | $19.4M | Sell |
130,821
-20,230
| -13% | -$2.82M | 0.03% | 548 |
|
|
2019
Q1 | $19.9M | Sell |
151,051
-4,706
| -3% | -$580K | 0.03% | 523 |
|
|
2018
Q4 | $16.9M | Sell |
155,757
-77,666
| -33% | -$10.4M | 0.03% | 533 |
|
|
2018
Q3 | $34.8M | Sell |
233,423
-32,457
| -12% | -$4.94M | 0.05% | 330 |
|
|
2018
Q2 | $41M | Buy |
265,880
+24,115
| +10% | +$3.64M | 0.07% | 257 |
|
|
2018
Q1 | $33.6M | Buy |
241,765
+21,502
| +10% | +$3.16M | 0.06% | 303 |
|
|
2017
Q4 | $30.2M | Buy |
220,263
+49,874
| +29% | +$6.59M | 0.06% | 321 |
|
|
2017
Q3 | $22.1M | Buy |
170,389
+15,797
| +10% | +$2.11M | 0.04% | 411 |
|
|
2017
Q2 | $20.5M | Buy |
154,592
+26,852
| +21% | +$3.29M | 0.04% | 431 |
|
|
2017
Q1 | $15.7M | Buy |
127,740
+21,051
| +20% | +$2.49M | 0.04% | 489 |
|
|
2016
Q4 | $11.8M | Buy |
106,689
+8,251
| +8% | +$917K | 0.03% | 555 |
|
|
2016
Q3 | $11.6M | Buy |
98,438
+9,922
| +11% | +$1.17M | 0.03% | 537 |
|
|
2016
Q2 | $9.91M | Buy |
88,516
+34,508
| +64% | +$3.71M | 0.03% | 540 |
|
|
2016
Q1 | $5.43M | Sell |
54,008
-11,294
| -17% | -$1.08M | 0.02% | 783 |
|
|
2015
Q4 | $6.94M | Buy |
65,302
+8,801
| +16% | +$908K | 0.02% | 660 |
|
|
2015
Q3 | $5.26M | Buy |
56,501
+5,829
| +12% | +$603K | 0.02% | 724 |
|
|
2015
Q2 | $5.28M | Sell |
50,672
-5,203
| -9% | -$542K | 0.02% | 789 |
|
|
2015
Q1 | $6.05M | Buy |
55,875
+26,824
| +92% | +$2.76M | 0.03% | 653 |
|
|
2014
Q4 | $2.69M | Sell |
29,051
-35,737
| -55% | -$3.16M | 0.01% | 998 |
|
|
2014
Q3 | $5.66M | Buy |
64,788
+16,219
| +33% | +$1.47M | 0.03% | 569 |
|
|
2014
Q2 | $4.27M | Buy |
+48,569
| New | +$4.21M | 0.03% | 698 |
|
|
2013
Q3 | – | Sell |
-26,624
| Closed | -$2.29M | – | 1948 |
|
|
2013
Q2 | $2.29M | Buy |
+26,624
| New | +$2.21M | 0.02% | 743 |
|
Other funds holding LH
Raymond James & Associates's LH Position: Q3 2024 in Review
Raymond James & Associates increased its Labcorp (LH) stake by 4.9% in Q3 2024, buying an estimated $1.27M and bringing the position to 124,336 shares worth $27.8M. The position accounts for 0.02% of the portfolio, ranked #656.
Raymond James & Associates first reported a position in LH in Q2 2013 and has held it in 43 quarters since. The position peaked at $41M in Q2 2018. 919 funds tracked by Wall St. Rank hold LH as of Q3 2024.
- Raymond James & Associates held 124,336 shares of Labcorp worth $27.8M as of Q3 2024.
- Raymond James & Associates bought 5,786 Labcorp shares in Q3 2024, an estimated $1.27M.
- Labcorp made up 0.02% of Raymond James & Associates's portfolio in Q3 2024, its #656 holding.
- Raymond James & Associates first reported a position in Labcorp in Q2 2013 and has held it in 43 quarters since.
- Raymond James & Associates's Labcorp position peaked at $41M in Q2 2018.
- 919 funds tracked by Wall St. Rank held Labcorp as of Q3 2024.
Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.